Overview

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Status:
Active, not recruiting

Trial end date:
2022-07-20

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Cytarabine
Venetoclax